Glycogen synthase kinase-3: A target for novel bipolar disorder treatments

Journal of Clinical Psychiatry

Volumn 65, Issue 1, 2004, Pages 10-21

  Gould, Todd D ^a,b   Zarate, Carlos A ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LITHIUM CARBONATE; TRANQUILIZER; TRANSCRIPTION FACTOR;

BIPOLAR DISORDER; HUMAN; INFLAMMATION; METABOLISM; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTIMANIC AGENTS; BIPOLAR DISORDER; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; LITHIUM CARBONATE; NEURONAL PLASTICITY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 1442284539     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0103     Document Type: Review

References (153)

1. Kusznir A, Cooke RG, Young LT. The correlates of community functioning in patients with bipolar disorder. J Affect Disord 2000;61:81-85
2. Ozer S, Ulusahin A, Batur S, et al. Outcome measures of interepisode bipolar patients in a Turkish sample. Soc Psychiatry Psychiatr Epidemiol 2002;37:31-37 (Pubitemid 36067950)
3. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000;61(suppl 13):38-41 (Pubitemid 32062304)
4. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-131 (Pubitemid 36044640)
5. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry 2003;64:425-432 (Pubitemid 36547287)
6. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990:938
7. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000;61(suppl 9):47-51 (Pubitemid 30453887)
8. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-3285 (Pubitemid 30842434)
9. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-592 (Pubitemid 28340345)
10. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med 1996;335:1176-1181 (Pubitemid 26339771)
11. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-495
12. Murray CJL, Lopez AD. The Global Burden of Disease Summary. Cambridge, MA: Harvard School of Public Health; 1996
13. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949;2:349-352
14. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002;63(suppl 10):5-12 (Pubitemid 35155102)
15. Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 2002;16:721-729 (Pubitemid 35252721)
16. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;359:1-16 (Pubitemid 32939202)
17. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776 (Pubitemid 33679839)
18. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE [serial online] Sept 18, 2001:RE12
19. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3b in cellular signaling. Prog Neurobiol 2001;65:391-426 (Pubitemid 32781670)
20. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41:789-813 (Pubitemid 32385907)
21. Gould TD, Chen G, Manji HK. Mood stabilizer psychopharmacology. Clin Neurosci Res 2002;2:193-212 (Pubitemid 35378647)
22. Amari L, Layden B, Rong Q, et al. Comparison of fluorescence, (31)P NMR, and (7)Li NMR spectroscopic methods for investigating Li(+)/ Mg(2+) competition for biomolecules. Anal Biochem 1999;272:1-7
23. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001;280:720-725 (Pubitemid 32924489)
24. York JD, Ponder JW, Majerus PW. Definition of a metal-dependent/ Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci U S A 1995;92:5149-5153
25. Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002;96:45-66 (Pubitemid 35346617)
26. Wang JF, Young LT, Li PP, et al. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, eds. Bipolar Disorder: Biological Models and Their Clinical Application. New York, NY: Dekker; 1997
27. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999;4:117-128 (Pubitemid 29163975)
28. Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 2000;61(suppl 9):5-15 (Pubitemid 30453881)
29. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105 (Pubitemid 30781561)
30. Shaldubina A, Agam G, Belmaker RH. The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:855-866 (Pubitemid 32374970)
31. Masuda CA, Xavier MA, Mattos KA, et al. Phosphoglucomutase is an in vivo lithium target in yeast. J Biol Chem 2001;276:37794-37801 (Pubitemid 37384023)
32. Rhyu GI, Ray WJ Jr, Markley JL. Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase: phosphorus NMR studies. Biochemistry 1984;23:252-260
33. Ray WJ Jr, Szymanki ES, Ng L. The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim Biophys Acta 1978;522:434-442 (Pubitemid 8274356)
34. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996;93:8455-8459 (Pubitemid 26269579)
35. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-1668 (Pubitemid 27050234)
36. Majerus PW. Inositol phosphate biochemistry. Annu Rev Biochem 1992;61:225-250
37. Naccarato WF, Ray RE, Wells WW. Biosynthesis of myo-inositol in rat mammary gland: isolation and properties of the enzymes. Arch Biochem Biophys 1974;164:194-201
38. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 1980;255:10896-10901 (Pubitemid 11171746)
39. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59:411-419 (Pubitemid 19284456)
40. Atack JR. Lithium, phosphatidylinositol signaling, and bipolar disorder. In: Manji HK, Bowden CL, Belmaker RH, eds. Bipolar Medications: Mechanism of Action. Washington, DC: American Psychiatric Press; 2000
41. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat New Biol 1971;233:267-268
42. Gould TD, Manji HK. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002;53:687-697 (Pubitemid 36292448)
43. Moore GJ, Bebchuk JM, Parrish JK, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry 1999;156:1902-1908
44. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999;46:1328-1351
45. Bebchuk JM, Arfken CL, Dolan-Manji S, et al. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania [letter]. Arch Gen Psychiatry 2000;57:95-97 (Pubitemid 30035669)
46. Fauroux CM, Freeman S. Inhibitors of inositol monophosphatase. J Enzyme Inhib 1999;14:97-108 (Pubitemid 29097602)
47. Atack JR. Inositol monophosphatase inhibitors: lithium mimetics? Med Res Rev 1997;17:215-224
48. Atack JR, Cook SM, Watt AP, et al. In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J Neurochem 1993;60:652-658
49. Atack JR, Prior AM, Fletcher SR, et al. Effects of L-690,488: a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers. J Pharmacol Exp Ther 1994;270:70-76
50. Pollack SJ, Atack JR, Knowles MR, et al. Mechanism of inositol monophosphatase: the putative target of lithium therapy. Proc Natl Acad Sci U S A 1994;91:5766-5770 (Pubitemid 24188222)
51. Bone R, Springer JP, Atack JR. Structure of inositol monophosphatase: the putative target of lithium therapy. Proc Natl Acad Sci U S A 1992;89:10031-10035
52. Moore CM, Demopulos CM, Henry ME, et al. Brain-to-serum lithium ratio and age: an in vivo magnetic resonance spectroscopy study. Am J Psychiatry 2002;159:1240-1242 (Pubitemid 34743271)
53. Gee JB II, Corbett RJ, Perlman JM, et al. Hypermagnesemia does not increase brain intracellular magnesium in newborn swine. Pediatr Neurol 2001;25:304-308 (Pubitemid 33026491)
54. Gotoh H, Kajikawa M, Kato H, et al. Intracellular Mg2+ surge follows Ca2+ increase during depolarization in cultured neurons. Brain Res 1999;828:163-168 (Pubitemid 29236487)
55. Li-Smerin Y, Levitan ES, Johnson JW. Free intracellular Mg(2+) concentration and inhibition of NMDA responses in cultured rat neurons. J Physiol 2001;533:729-743
56. Brocard JB, Rajdev S, Reynolds IJ. Glutamate-induced increases in intracellular free Mg2+ in cultured cortical neurons. Neuron 1993;11:751-757 (Pubitemid 23321782)
57. Amari L, Layden B, Nikolakopoulos J, et al. Competition between Li+ and Mg2+ in neuroblastoma SH-SY5Y cells: a fluorescence and 31P NMR study. Biophys J 1999;76:2934-2942
58. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology [serial online] Aug 27, 2003
59. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-3305 (Pubitemid 28023954)
60. Moon RT, Bowerman B, Boutros M, et al. The promise and perils of Wnt signaling through β-catenin. Science 2002;296:1644-1646 (Pubitemid 34579151)
61. Lee CW, Lau KF, Miller CC, et al. Glycogen synthase kinase-3β- mediated tau phosphorylation in cultured cell lines. Neuroreport 2003;14:257-260 (Pubitemid 36308422)
62. Bhat RV, Shanley J, Correll MP, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 2000;97:11074-11079 (Pubitemid 30751280)
63. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium. Neuropharmacology 2002;43:1158-1164 (Pubitemid 36009369)
64. Zhang F, Phiel CJ, Spece L, et al. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium: evidence for autoregulation of GSK-3. J Biol Chem 2003;278:33067-33077 (Pubitemid 37055753)
65. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/ threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999;96:8745-8750 (Pubitemid 29354862)
66. Hall AC, Brennan A, Goold RG, et al. Valproate regulates GSK-3- mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 2002;20:257-270 (Pubitemid 34762135)
67. Lochhead PA, Coghlan M, Rice SQ, et al. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolpyruvate carboxykinase gene expression. Diabetes 2001;50:937-946 (Pubitemid 32374522)
68. Kleijn M, Proud CG. The activation of eukaryotic initiation factor (eIF)2B by growth factors in PC12 cells requires MEK/ERK signalling. FEBS Lett 2000;476:262-265 (Pubitemid 30410829)
69. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, et al. Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation. Oncogene 2001;20:252-259 (Pubitemid 32150270)
70. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993;296:15-19 (Pubitemid 23344723)
71. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3β in intact cells via serine 9 phosphorylation. Biochem J 1994;303:701-704 (Pubitemid 24325998)
72. Eldar-Finkelman H, Seger R, Vandenheede JR, et al. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem 1995;270:987-990
73. Russell DS, Duman RS. Neurotrophic factors and intracellular signal transduction pathways. In: Davis KL, Charney DS, Coyle JT, et al, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002
74. Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord 2002;4:89-104
75. Soares JC. Can brain-imaging studies provide a "mood stabilizer signature"? Mol Psychiatry 2002;7(suppl 1):S64-S70
76. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001;11:240-249 (Pubitemid 32289413)
77. Sheline VI, Mintun MA. Structural and functional imaging of affective disorders. In: Davis KL, Charney DS, Coyle JT, et al, eds. Psychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002
78. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002;125:1428-1449 (Pubitemid 34755160)
79. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000;48:766-777 (Pubitemid 30813462)
80. Lenox RH, Gould TD, Manji HK. Endophenotypes in bipolar disorder. Am J Med Genet 2002;114:391-406 (Pubitemid 34525236)
81. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541-547 (Pubitemid 32448319)
82. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-827 (Pubitemid 27181254)
83. Maggirwar SB, Tong N, Ramirez S, et al. HIV-1 Tat-mediated activation of glycogen synthase kinase-3β contributes to Tat-mediated neurotoxicity. J Neurochem 1999;73:578-586 (Pubitemid 29339830)
84. Hetman M, Cavanaugh JE, Kimelman D, et al. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000;20:2567-2574 (Pubitemid 30220344)
85. Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β. J Biol Chem 2001;276:37436-37442 (Pubitemid 37384167)
86. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932 (Pubitemid 28377539)
87. Takashima A, Noguchi K, Sato K, et al. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 1993;90:7789-7793 (Pubitemid 23250036)
88. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803
89. Cross DA, Culbert AA, Chalmers KA, et al. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001;77:94-102 (Pubitemid 32245083)
90. Ding S, Wu TY, Brinker A, et al. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A 2003;100:7632-7637 (Pubitemid 36760021)
91. Huang H, Mahler-Araujo BM, Sankila A, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-437 (Pubitemid 30643798)
92. Koch A, Waha A, Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 2001;93:445-449 (Pubitemid 32592067)
93. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist 2002;8:497-511
94. Salinas PC. Wnt factors in axonal remodelling and synaptogenesis. Biochem Soc Symp 1999;65:101-109 (Pubitemid 129541616)
95. Hall AC, Lucas FR, Salinas PC. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 2000;100:525-535
96. Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 2002;297:365-369 (Pubitemid 34790759)
97. Spittaels K, Van den Haute C, Van Dorpe J, et al. Neonatal neuronal overexpression of glycogen synthase kinase-3b reduces brain size in transgenic mice. Neuroscience 2002;113:797-808 (Pubitemid 35245250)
98. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999;46:929-940
99. Chuang DM, Chen R, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002;4:129-136 (Pubitemid 34411275)
100. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998;9:2081-2084 (Pubitemid 28300570)
101. Ren M, Senatorov VV, Chen RW, et al. Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci U S A 2003;100:6210-6215 (Pubitemid 36576955)
102. Wei H, Qin ZH, Senatorov VV, et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001;106:603-612 (Pubitemid 32925248)
103. Chen G, Rajkowska G, Du F, et al. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000;75:1729-1734 (Pubitemid 30694692)
104. Son H, Yu IT, Hwang SJ, et al. Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 2003;85:872-881 (Pubitemid 36578619)
105. Hashimoto R, Senatorov V, Kanai H, et al. Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 2003;117:55-61 (Pubitemid 36246503)
106. Moore GJ, Bebchuk JM, Hasanat K, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000;48:1-8
107. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000;356:1241-1242 (Pubitemid 30769496)
108. Sassi R, Nicoletti M, Brambilla P, et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002;329:243-245 (Pubitemid 34880083)
109. Silverstone PH, Wu RH, O'Donnell T, et al. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003;18:73-79 (Pubitemid 36343975)
110. Wehr TA, Sack D, Rosenthal N, et al. Circadian rhythm disturbances in manic-depressive illness. Fed Proc 1983;42:2809-2814
111. Wirz-Justice A, Van den Hoofdakker RH. Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 1999;46:445-453
112. Payne JL, Quiroz JA, Zarate CA Jr, et al. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 2002;52:921-926
113. Wehr TA. Sleep loss: a preventable cause of mania and other excited states. J Clin Psychiatry 1989;50(12, suppl):8-16, 45-47 (Pubitemid 20015275)
114. Klemfuss H. Rhythms and the pharmacology of lithium. Pharmacol Ther 1992;56:53-78 (Pubitemid 23070497)
115. Martinek S, Inonog S, Manoukian AS, et al. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 2001;105:769-779
116. Reppert SM, Weaver DR. Comparing clockworks: mouse versus fly. J Biol Rhythms 2000;15:357-364 (Pubitemid 30758411)
117. Wager-Smith K, Kay SA. Circadian rhythm genetics: from flies to mice to humans. Nat Genet 2000;26:23-27 (Pubitemid 30692851)
118. Williams JA, Sehgal A. Molecular components of the circadian system in Drosophila. Annu Rev Physiol 2001;63:729-755 (Pubitemid 32304336)
119. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002;8:126-132 (Pubitemid 34532638)
120. Kaidanovich O, Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 2002;6:555-561 (Pubitemid 35189532)
121. Alvarez G, Munoz-Montano JR, Satrustegui J, et al. Regulation of tau phosphorylation and protection against β-amyloid-induced neurode generation by lithium: possible implications for Alzheimer's disease. Bipolar Disord 2002;4:153-165 (Pubitemid 34591242)
122. Sun X, Sato S, Murayama O, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 2002;321:61-64 (Pubitemid 34185499)
123. Phiel CJ, Wilson CA, Lee VM, et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003;423:435-439 (Pubitemid 36626994)
124. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 2000;406:86-90 (Pubitemid 30460216)
125. Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res 2002;90:377-379 (Pubitemid 34633905)
126. Dorronsoro I, Castro A, Martinez A. Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs. Expert Opin Ther Patents 2002;12:1527-1536 (Pubitemid 35175213)
127. Martinez A, Castro A, Dorronsoro I, et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373-384 (Pubitemid 34620473)
128. Leclerc S, Garnier M, Hoessel R, et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease: a property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001;276:251-260
129. Ma MZ, Yao BY. Progress in indirubin treatment of chronic myelocytic leukemia. J Tradit Chin Med 1983;3:245-248
130. Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999;1:60-67 (Pubitemid 129495012)
131. Hers I, Tavare JM, Denton RM. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett 1999;460:433-436 (Pubitemid 29518414)
132. Smith DG, Buffet M, Fenwick AE, et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 2001;11:635-639 (Pubitemid 32187945)
133. Culbert AA, Brown MJ, Frame S, et al. GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 2001;507:288-294 (Pubitemid 33030251)
134. Martinez A, Alonso M, Castro A, et al. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-1299 (Pubitemid 34263565)
135. Plotkin B, Kaidanovich O, Talior I, et al. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003;305:974-980 (Pubitemid 36621426)
136. Dajani R, Fraser E, Roe SM, et al. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001;105:721-732
137. Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-677 (Pubitemid 32144195)
138. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000;151:117-130 (Pubitemid 30761125)
139. De Strooper B, Woodgett J. Alzheimer's disease: mental plaque removal. Nature 2003;423:392-393 (Pubitemid 36626980)
140. Cohen Y, Chetrit A, Sirota P, et al. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 1998;15:32-36 (Pubitemid 28248297)
141. Gould TD, Gray NA, Manji HK. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res 2003;48:49-53 (Pubitemid 36593358)
142. El-Domeiri AA, Messiha FS, Hsia WC. Effect of alkali metal salts on Sarcoma I in A/J mice. J Surg Oncol 1981;18:423-429 (Pubitemid 12202330)
143. Ballin A, Aladjem M, Banyash M, et al. The effect of lithium chloride on tumour appearance and survival of melanoma-bearing mice. Br J Cancer 1983;48:83-87
144. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408 (Pubitemid 24026101)
145. Fawcett JA. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. J Clin Psychiatry 2003;64(suppl 5):32-37 (Pubitemid 36539129)
146. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645 (Pubitemid 41079594)
147. Lesort M, Greendorfer A, Stockmeier C, et al. Glycogen synthase kinase-3β, β-catenin, and tau in postmortem bipolar brain. J Neural Transm 1999;106:1217-1222 (Pubitemid 30009217)
148. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 2001;52:101-105 (Pubitemid 32947052)
149. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000;157:831-833 (Pubitemid 30249669)
150. Beasley C, Cotter D, Everall I. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res 2002;58:63-67 (Pubitemid 35287284)
151. Manji HK, Moore GJ, Rajkowska G, et al. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5:578-593
152. Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003;38:157-160 (Pubitemid 36555643)
153. Nikoulina SE, Ciaraldi TP, Mudaliar S, et al. Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 2002;51:2190-2198 (Pubitemid 34729024)